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1. INTRODUCTION 
1.1 Cannabis plant 
 
Cannabis is one of the most controversial substances of the twenty-
first century. The genus Cannabis is a member of the family plant 
Cannabaceae, and the primary cannabis species are Cannabis sativa, 
Cannabis indica and Cannabis ruderalis, which vary in their biochemical 
constituents.1 Marijuana is the dry shredded green mixture of flower, stem, 
seeds and leaves of the Cannabis sativa. Botanical origins of cannabis are 
probably from Western and Central Asia. Cannabis has been cultivated 
since ancient times in Asia and Europe and then spread to America.2  
The plant chemistry is very complex: it has over 421 different 
compounds, including over 60 phytocannabinoids, divided into 18 different 
classes of chemicals such as nitrogenous components, amino acids, 
hydrocarbons, carbohydrates, terpenes, and simple and fatty acids. In 
addition, there are more than 2,000 compounds that may be released after 
pyrolysis3-5. Δ9-Tetrahydrocannabinol (Δ9-THC, from now on THC) is the 
main psychoactive, as well as the most studied among the cannabis 
components.6 Others major cannabinoids in Cannabis sativa plant are 
cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN), that 
present less and different psychoactive effects from THC.  
THC content in a plant can range from 0.4% up to 20%, depending 
on the strain, available light, soil type and pH, nutrients and fertilizers 
provided and time of harvest.7-9 Over the past decades, the amount of THC 
in cannabis strains has been increasing steadily.10  
The most potent early strain is the sinsemillas, a seedless marijuana 
from the inflorescences of the female plants. Other more common strains, 
known for their potency, are the Purple Haze, Early Girl, Big Bud, Skunk, 
Superskunk and Hindu Kush. The exposure to the plant occurs mainly 
through inhalation of cigarettes smoke (joints) or pipes (bongs) or through 
ingestion of different food products such as cakes, cookies, and candies. 
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Hashish, a potent cannabis derivative, is made from the resin collected from 
the tops of flowering plants. Often, hashish contains THC levels that exceed 
10%.11 Hash oil, another form of cannabis product, could contain even 
higher THC concentrations, up to 20%. A joint usually contains 500-1000 
mg of plant material, corresponding to 15-30 mg of THC.12,13  
Through the decades, the ideology around cannabis has taken a 
swinging journey from an illegal to a legal status. In the United States, in 32 
states marijuana has been already legalized for medicinal use, in 9 states 
for recreational use, and decriminalized in another 14 states. In Italy, the 
therapeutic use of cannabis has been authorized since 2007 and nowadays 
personal possession and supply has been sensitively decriminalized 
compared to other drugs.14  
 
1.2 Cannabis effects 
 
Due to its many medicinal properties, cannabis has many uses since 
the ancient times.15 The growing interest for the multitude of its potential 
medicinal uses has led to a significant pressure for legalizing medicinal 
cannabis and the research related to possible applications. To date, several 
pharmaceutical products containing different compositions and 
concentrations of THC and CBD have already received regulatory approvals 
(Sativex®, Marinol®, Cesamet®) or are under investigation as potential 
treatments of diseases such as anorexia-cachexia syndrome, 
chemotherapy-induced emesis, glaucoma and pain and spasticity in 
Multiple Sclerosis.16, 17  
Moreover, cannabis is currently the most commonly used illicit drug 
on earth18, 19. Exposure to THC causes different effects varying from 
euphoria, palpitations, heightened sensory awareness, to altered time 
perception and coordination.20 Occasionally, even low doses of THC, may 
precipitate a panic reaction, disrupt motor activities, alter nociception, and 
cause nausea and vomiting.21, 22 Higher concentrations of THC could lead 
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to anxiety, impaired short-term memory, depersonalization, hallucinations, 
acute paranoid psychosis, tachycardia, orthostatic hypotension, 
conjunctival injection, incoordination, slurred speech, and ataxia.20, 23 
Furthermore, long term cannabis use is associated with impairment 
of learning and memory, attention, working memory,24, 25 executive 
functions, motor skills and verbal abilities.26,27 
In addition, recent preclinical and clinical findings support the 
association between cannabis and amotivational syndrome.28, 29 Since THC 
has proven to be able to disrupt learning, the reduced motivation has been 
suggested to be a pathway to impaired learning.30 Interestingly, cannabis 
users show a reduction in striatal dopamine synthesis capacity,31 with an 
inverse relationship to amotivation. Whereas dopamine sustains circuits of 
motivation, it was theorized that an impaired dopamine synthesis could be 
related to the loss of motivation in cannabis users.32  
In the central nervous system (CNS), cannabis is known to act 
through two types of receptors. Cannabinoid receptors type 1 (CB1Rs) are 
distributed all over the central nervous system and associated with most of 
the CNS endocannabinoid signaling33, while CB2Rs are mainly expressed 
in immune system cells. CB1R and CB2R are coupled to inhibitory Gi/o-
proteins.34, 35 THC activity on mesocortical and limbic systems, striatum and 
lateral prefrontal cortex, has been suggested to be the cause of the main 
clinical effects of cannabis.36, 37  
There is an endogenous system of ligands for cannabinoid receptors 
(i.e., 2-arachidonoyl glycerol, anandamide, and N-palmitoylethanolamide) 
that act like neurotransmitters.38 This system is crucial in various functions 
involving memory, emotions, movement, cell proliferation, and other 
important cell functions.39 Cannabis, as well as other drugs of abuse, alters 
brain levels of endocannabinoids, therefore, part of the complexity of 
cannabis-mediated effects could to be due to its role on this endogenous 
system, proven to be involved also in processes of drug reward. Despite the 
massive research on neuronal cell cultures40, 41, rodents,42, 43 monkeys,44, 45 
and human brains, the mechanisms underlying cannabis effects and toxicity 
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are still not completely elucidated.46  
 
1.3 Cannabis and ammonia 
 
In a recent study, high concentrations of ammonia were detected in 
the cannabis smoke and vapor from the heated cannabis plant. 47 It has also 
been proved that stressing the cannabis plant by UV exposure, increases 
the content of THC and ammonia. 48 Back in time, De Pasquale et al. 
demonstrated how chronic parenteral administrations of cannabis resin in 
dogs can significantly increase blood ammonia concentrations.49 A few 
years later, Ghoneim et al., proved that exposing rabbits to hashish smoke 
for one month, markedly increased their blood ammonia concentrations.50 
Moreover, inhaled ammonia released during smoking has been shown to be 
quickly absorbed through the lungs into the systemic circulation, where it 
diffuses passively through the blood brain barrier (BBB).51  
The ammonia dynamics within the central nervous system (CNS) has 
been widely studied in several diseases, among all the hepatic 
encephalopathy and acute liver failure. Although the exact pathophysiology 
of hyperammonemia is still matter of debate, one recognized factor is that 
increased brain ammonia triggers its own detoxification by glutamine 
synthesis from glutamate by astrocytic glutamine synthetase (GS) 
enzyme.52,53  
The glutamine produced in astrocytes is normally used as source of 
energy or, is converted into glutamate by the neuronal glutaminase (GA), 
with the release of ammonia (Figure 1).54 
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Figure 1. Representative scheme of ammonia cycle in blood, astrocytes and 
neurons. Ammonia inhaled with cannabis smoke diffuses into the systemic circulation and 
then passively through the blood brain barrier (BBB). Ammonia is included into glutamine 
by astrocytic glutamine synthetase. Astrocytic glutamine can be shuttled to glutamatergic 
neurons where it is converted into glutamate by glutaminase. 
   
In the astrocytes, part of the brain glutamine can be replaced with 
neutral amino acids such as tryptophan, phenylalanine, and tyrosine from 
the blood.55, 56, 57 Under normal conditions brain GS operates at near 
maximum capacity.55, 58, 59  
Indeed, under physiological conditions, the ammonia released from 
neurons in the glutamate–glutamine cycle (during glutamate synthesis from 
glutamine) is used in same amounts for the synthesis of glutamine from 
glutamate in astrocytes, with no net ammonia production. In conditions of 
ammonia excess instead, the main mechanism of detoxification is the 
glutamate conversion into glutamine that, accumulating within the 
astrocytes may interferes with mitochondrial function and increase the 
production of free radicals. [25]  or decreasing glutamate levels, interfering 
with neuronal transmission. 60, 61 
Furthermore, increased glutamine can produce an enhancement in 
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brain tyrosine and tryptophan concentrations, promoting consequently 
dopamine and serotonin synthesis (Figure 2).62 
 
Figure 2. Representative scheme of ammonia cycle in blood, astrocytes and 
neurons. Glutamine synthetized in astrocytes can be exchanged with tryptophan, 
phenylalanine, and tyrosine from the brain to the blood and consequently promotes 
dopamine and serotonin synthesis. 
 
Several in vivo and in vitro studies reported that high ammonia 
concentrations in the brain have toxic effects on neurons, astrocytes and 
mitochondria, but how ammonia brings changes in these types of cells is 
not totally understood.  
The critical factor in ammonia‐induced cell impairment seems to be 
the oxidative/nitroxidative stress. One consequence of oxidative stress is 
the induction of the mitochondrial permeability transition, a Ca2+‐dependent 
process associated with a collapse of the inner mitochondrial membrane 
potential due to the opening of the permeability transition pore. Such 
membrane potential collapse leads to mitochondrial dysfunction, energy 
failure and additional free radical production.63  
Secondary ammonia-mediated alterations are changes in neuronal 
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firing patterns,64 activation of glutamatergic signaling65 and swelling of 
astrocytes.66 This last condition is also a major component of the brain 
edema associated with hyperammonemic state. 
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2. AIM OF THE THESIS 
 
Either if marijuana is used for medicinal or recreational purposes, 
novel therapeutic targets that can effectively treat cannabis-related side 
effects are urgently needed and a better understanding of the mechanisms 
underlying cannabis effects seems crucial.  
For this reason, our aim is to study the potential link to cannabis and 
ammonia, a new potential target to treat cannabis side effects. In order to 
do this, we quantified how cannabis is able to vary ammonia concentrations 
over time in healthy cannabis users and mice. Moreover, we aim also to 
investigate the causal relationship between cannabis-induced transient 
hyperammonemia and acute changes in locomotor activity at a neuronal 
level. 
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3. MATERIALS AND METHODS  
  
3.1 Clinical Study 
  
The study protocol was approved by the National Institute on Drug 
Abuse Institutional Review Board and all participants provided written 
informed consent. Clinical procedures took place at the NIDA – IRP, 
Baltimore, USA (ClinicalTrials.gov Identifier NCT02177513). 
 
  3.1.1 Study design  
 
The clinical trial was designed as double blind, placebo-controlled, 
randomized, four-session crossover study. For the main clinical trial, 28 
healthy volunteers that used to smoke cannabis ≥2x/month were recruited. 
However, in this thesis only the effect of controlled cannabis administration 
on plasma ammonia concentrations in a subgroup of subjects (n=14) will be 
reported, due to the late inclusion of plasma ammonia concentration within 
the clinical parameters evaluated in the ongoing main study. 
 Inclusion criteria for the recruitment were: - males and females from 
18 to 50 years of age; - consuming cannabis in the past 3 months; - one 
urine screening positive for cannabinoid for frequent cannabis smokers. 
Exclusion criteria were: - use of cannabis for medical purposes; - history of 
significant adverse events associated to cannabis; - current physical 
dependence on any drug other than cannabis, caffeine, or nicotine; - 
presence or history of clinically significant illness; - pregnant or nursing 
females. Women in child bearing age were required to use an accepted 
method of contraception.   
Primary outcomes included subjective and objective assessments, 
performance on neurocognitive and motor tasks, and cannabinoid 
concentrations in whole blood, oral fluid, urine, dried blood spots, and 
breath.  
During each of the four sessions, subjects were administered with a 
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placebo or active oral cannabis dose, followed by either placebo or active 
smoked or vaporized cannabis. Only one active and one placebo dose were 
administered in each dosing session. Possible combinations were: active 
brownie and placebo vaporized, or active brownie and placebo cigarette, or 
placebo brownie and active vaporized, or placebo brownie and active 
cigarette or two placebo doses [placebo brownie and placebo vaporized, or 
placebo brownie and placebo cigarette]. The order for all four sessions was 
randomly assigned. 
Participants consumed the oral, followed by the smoked or vaporized 
dose over 10 min. During the session, before the administration (time point 
0) and at 2, 4, 6, 8, 10, 15, 30, and 90 min after the beginning of cannabis 
administration, blood samples were collected for the determination of 
plasma ammonia and blood THC levels. 
The four sessions were schedule with a minimum interval of 72 
hours, and, when not hospitalized, the patients were allowed to use 
cannabis between sessions. 
 
  3.1.2 Drugs 
 
Natural cannabis inflorescence and placebo (containing 0.001 mg 
THC) were provided by the NIDA pharmacy. For the routes of administration 
by inhalation (smoke and vapor), cannabis doses (54 mg THC) were 
prepared as a cigarette, or the same quantity was extracted and delivered 
via a Volcano® vaporizing device (Storz and Bickel, Germany) 67. For the 
oral doses, brownies were prepared following the Duncan Hiness Double 
Fudge® cake-like brownie instructions: the contents of an active or placebo 
cigarette were ground, baked for 30 min at 121 °C in aluminum foil, and 
mixed into equal portions of batter in a muffin tin.  
 
3.1.3 Procedures 
 
During each session, ten blood samples were collected in two 
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aliquots 0, 2, 4, 6, 8, 10, 15, 30, and 90 min after the beginning of cannabis 
administration in order to measure plasma ammonia concentrations and 
THC blood levels.  
 
Plasma ammonia concentration. All the samples were collected in 
pre-cooled heparinized tubes and immediately centrifuged at 3000g (4°C) 
for 3 min. Plasma was collected at 4°C and ammonia concentrations were 
assayed with a commercial colorimetric assay kit (BioVision Inc., Milpitas, 
CA) according to the manufacturer’s instructions. Every sample was 
assayed in duplicate. Ammonia concentration was detected with a 
Sunrise™ microplate absorbance reader (Tecan Group Ltd., Männerdorf, 
Switzerland). The inter-assay coefficient of variance of controls was <10%.  
 
THC blood concentration. Blood samples collected at different time 
points were processed according to a previously published method. 68 
Briefly, 100 µL of human blood was deproteinized with acetonitrile and 
cannabinoids were extracted from the supernatants using disposable 
pipette extraction WAX-S tips (DPX Labs, Columbia, SC, USA). An aliquot 
of the resulting organic phase was diluted with aqueous mobile phase, 
centrifuged, and injected into the Liquid chromatography tandem-mass 
spectrometry (LC-MS/MS) system. Linear ranges were 0.5–100 µg/L. Intra- 
and inter-day imprecision were 2.4–8.5%, and the accuracy was 88.9–
115%. 
 
3.2 Animal Study 
 
3.2.1 Animals 
 
All experimental protocols were conducted in accordance with U.S. 
National Institutes of Health Guidelines for the Care and Use of Laboratory 
Animals and with the approval of the National Institute on Drug Abuse 
Animal Care and Use Committee. All the in vivo electrophysiology 
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experiments were carried out in accordance with the United States National 
Research Council Guide for the Care and Use of Laboratory Animals and 
were approved by the University of Maryland School of Medicine 
Institutional Animal Care and Use Committee. For all the experiments, one 
to six-month-old male C57BL/6J (wild-type, Strain 664, The Jackson 
Laboratory, ME, USA) mice were used. Prior to each procedure, mice were 
group housed in temperature and humidity-controlled rooms with ad libitum 
access to water and rodent chow (PicoLab Rodent Diet 20, 5053 tablet, 
LabDiet/Land O’Lakes Inc., MO, USA) on a 12 h light/dark cycle.  
 
3.2.2 Drugs 
 
Natural THC was provided by the NIDA pharmacy and prepared for 
injection by adding THC to TWEEN® 80 (Sigma Aldrich, St. Louis, MO) and 
0.9% saline 1:1:18 (v:v:v). 69 The total volume injected ranged between 0.25 
mL and 0.35 mL depending on the THC concentration and the animal 
weight. 
The CB1 receptor neutral antagonist NESS 0327 (Cayman 
Chemicals, Ann Arbor, Michigan) was dissolved in a solution of TWEEN® 
80, DMSO (Sigma Aldrich, St. Louis, MO) and 0.9% saline 1:2:7 (v:v:v).69 
 
3.2.3 Open Field Test 
 
Effect of THC on spontaneous locomotor activity. In order to 
determine which THC dose could cause a significant reduction in 
spontaneous locomotor activity, three groups of mice (n=32 each, n=8/each 
subgroup) were used. The first group was treated with THC 0 mg/kg (vehicle 
control: TWEEN 80® and saline), the second with a low dose of THC (3 
mg/kg) and the last one with a high dose of THC (10 mg/kg). Spontaneous 
locomotor activity (distance traveled) was observed for 5 minutes before the 
THC/ vehicle intraperitoneal (i.p.) injection and 1-, 3-, 5- and 30-min post-
administration (timepoint 0), depending on the subgroup (Fig. 4). For every 
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main group, we used four subgroups (n=8 each) for different time of 
euthanasia (1-, 3-, 5- and 30-min post dose).  
Each mouse was placed in a plexiglass open field (OF) arena (32x32 cm) 
and the distance travelled was recorded with a video-tracking system and 
then analyzed with a VersaMax software (AccuScan Instruments Inc., 
Columbus, OH).  
 
Effect of CB1R antagonist NESS 0327 in reversing the effect of 
THC on locomotor activity. One group of mice (n=15) was administered 
with NESS 0327 (i.p., 0,1 mg/kg) 30 min prior THC/vehicle injection (n=7-
8/treatment, respectively), then animals were placed in a plexiglass OF 
arena and the entire session was video recorded for 5 minutes before and 
up to 20 min after THC injection. Data were analyzed with AnyMaze 
software (Wood Dale, IL).  
 
Identification of the best dose of ammonium acetate to mimic 
THC effect on locomotor activity. Four groups of mice were used for this 
experiment (n=7 each). Mice were placed in a OF arena, distance travelled 
recorded for a 5-minute baseline, then treated with i.p. injections of vehicle 
control (distilled water), NH4Ac 1 mM/kg, 3 mM/kg or 5 mM/kg. After the 
injections, mice were replaced in the arena and movements recorded for 20 
minutes. Data were analyzed with AnyMaze software (Wood Dale, IL). 
 
3.2.4 Ammonia and THC quantification 
 
Euthanasia, blood collection. Following cervical dislocation, mice 
(8 animals/subgroup) were euthanized by rapid decapitation at 1, 3, 5 and 
30 min. Trunk blood was collected in precooled (4 °C) heparinized tubes 
and centrifuged immediately [3000g (4 °C) x 3 min]. Collected mouse 
plasma was divided into 2 aliquots, one was stored at −20 °C for the 
determination of THC levels and the second one was used immediately for 
the colorimetric ammonia assay. Moreover, immediately following 
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decapitation also liver, prefrontal cortex (PFC), striatum (ST) and 
cerebellum (Cere) were dissected on ice water (4 °C) under a light 
microscope and transported on dry ice to a −80 °C freezer until assayed for 
ammonia concentration and enzymatic activity. 
 
Blood and Plasma THC quantification. Mouse plasma samples (20 
µL) were processed and THC quantification was performed as described 
above for the human blood samples.  
 
Ammonia determination in plasma, liver and brain tissues. 
Mouse plasma (25 µL) was deproteinized with an equal volume of 8% 
perchloric acid and centrifuged at 4000g (4 °C) for 5 min. Specimens were 
neutralized with 2 M potassium bicarbonate and re-centrifuged at 4000g 
(4 °C) for 10 min prior to the analysis. Following the last collection, 
specimens were analyzed using a commercial ammonia colorimetric assay 
kit (Abcam®), following the manufacturer’s instructions as mentioned 
above. 
Brain and liver tissues were homogenized in 20 times w/v of ice-cold 
ammonia kit buffer (Abcam®) and centrifuged at 4000g (4 °C) for 5 min and 
processed as above.  
We performed the experiments for ammonia quantification in the afternoon 
(between 1-6PM) to reduce the physiological variability in plasma ammonia 
concentration during the day.70 
 
3.2.5 Glutamine synthetase and glutaminase enzymatic activity 
 
 To assess the glutamine synthetase (GS) enzymatic activity, brain 
tissues were homogenized in 20 times (w/v) of 60 mM imidazole-HCl buffer 
(pH 7.5) containing EDTA and spun at 1000g for 10 min at 4°C. GS 
enzymatic activity was assessed as described by Momosaki et al.71: 
supernatant was incubated with a 60 mM L-glutamine, 15 mM 
hydroxylamine HCl, 20 mM Na-arsenite, 0.4 mM ADP, 3 mM MnCl2, and 60 
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mM imidazole-HCl buffer solution, for 15 min at 37ºC, 1:10 v:v. The reaction 
was stopped by adding 1:1 v:v of a solution of 0.05 M trichloroacetic acid, 
0.16 M HCl and 1.18 M FeCl3) and incubated for 5 min at 37°C. Absorbance 
of the product of the reaction, the glutamyl hydroxamate, was assayed with 
a Sunrise™ microplate absorbance reader at 540nm. GS activity is 
expressed as mM of γ-glutamyl hydroxamate/min/mg of proteins. To assess 
the protein content a Pierce™ BCA Protein Assay Kit was used 
(ThermoFisher®, Halethorpe, MD). 
To quantify the glutaminase (GA) enzymatic activity, brain tissues were 
homogenized in 20 times of buffer containing 25 mM Tris–HCl, 0.2 mM 
EDTA, 0.33 M sucrose. Samples were then solubilized with Triton (TX-100) 
and spun at 100,000g for 30 min.68 The enzyme activity was assayed as 
previously described71, 72. Twenty-five μL supernatant was incubated for 1 h 
at 37°C with 35 μL of reagent mixture (Reagent 1, 100 mM potassium 
phosphate, 171 mM L-glutamine and 1.5 mM NH4Cl). The reaction was 
stopped with the addition of 10 μL 10% tricarboxylic acid. Blanks and 
reagent 1 were incubated separately and then mixed after the addition of 
tricarboxylic acid. Samples and blanks were spun at 4,000g for 10 min. A 5 
μL aliquot was add to 150 μL of a second reagent (0.2 M potassium 
phosphate, 72 mM mercaptoethanol in ethanol and 186 mM o-
phthalaldehyde in ethanol). Samples were incubated at room temperature 
for 45 min in the dark. The absorbance was measured at 405 nm and 
compared to the absorbance generated by a standard curve of NH4Cl 
treated with the reagent 2. GA activity is expressed as mM of ammonia 
produced/min/mg of proteins as previously reported.71 
 
3.2.6 Functional imaging of neuronal activity of dorsolateral 
striatal neurons 
 
Stereotaxic viral injections and GRIN lens implantation. For 
GRIN lens implantation surgeries, six to eight-week-old wildtype mice were 
used. Each animal was unilaterally implanted in either the left or right 
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hemisphere. Mice were anesthetized with isoflurane and placed onto a 
stereotaxic apparatus (David Kopf Instruments, CA, USA). After exposing 
the skull by a minor incision, a small hole (< 1 mm diameter) was drilled for 
virus injection and subsequent GRIN lens implantation. First, a beveled 25-
gauge needle was inserted into the hole to create a guide path for the lens 
(needle: bregma, +0.75 mm; midline, ±1.90 mm; dorsal surface, 2.55 mm). 
Next, an adeno-associated virus (rAAV2.9/CAG.GCaMP6s.WPRE.SV40, 
titer: 1.34×1013 genomic copies/ml; University of Pennsylvania Gene 
Therapy Program Vector Core, PA, USA)73was injected (100 nl; rate: 30 
nl/min) into the dorsolateral striatum (injection: bregma+0.75 mm; midline, 
±1.90 mm; dorsal surface, 2.70 mm) by a pulled glass pipette (2030 µm 
tip diameter) with a micromanipulator (Narishige International USA Inc., NY, 
USA) controlling the injection speed. After injection, either a GRIN lens (ILW-
050-P146-055-NC; Go!Foton Corporaton, NJ, USA) or a cannula 
(MGC_560/610_5.2_v2.1;  Doric Lenses Inc., QC, Canada)74 was lowered 
into position above the injection site (lens: bregma+0.75 mm; midline, ±1.90 
mm; dorsal surface, 2.20 mm). A head bar was attached to the skull surface 
with cyanoacrylate and dental cement (C&B Metabond Adhesive Cement, 
Parkell Inc., NY, USA) was spread around the lens or cannula and inside 
the head bar to hold everything in place. A final layer of black dental cement 
(Contemporary Ortho-Jet, Lang Dental Manufacturing Company Inc., IL, 
USA) was applied around the lens or cannula on top of the previous layer 
of cement. Two layers Parafilm were used to cover the GRIN lens or 
cannula, and the inside of the head bar was filled with Kwik-Sil (World 
Precision Instruments, FL, USA). After surgery, mice were individually 
housed. 
Intraperitoneal catheter placement. Three days before the imaging 
experiment, mice were implanted with custom made catheters (Micro-
Renathane® Tubing – Braintree scientific, Braintree, MA) for i.p. infusion. 
Inhalation anesthesia was maintained throughout surgeries with isoflurane 
via an E-Z Anesthesia brand vaporizer (E-Z Anesthesia, Palmer, PA). The 
incision site was sterilized with iodine and isopropyl alcohol. A small 
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abdominal incision of about 5 mm was made through the skin and 
peritoneum to implant the flexible tube. The tube was fixed to the internal 
abdominal wall with silk sutures to maintain the placement. The catheter 
terminals were guided with a trocar under the skin and exposed on the back 
of the mice, between the shoulders, to allow injections under the two-photon 
endomicroscopy setup.  
 
Two-photon fluorescence endomicroscopy recording. We 
obtained three-dimensional resolution images of dorsolateral striatal 
neurons across sessions by using two-photon fluorescence 
endomicroscopy in awake, head-fixed mice. We used singlet (ILW-050-
P146-055-NC; Go!Foton Corporation) GRIN lenses for tissue imaging in 
mice. The singlet lens has a working distance of approximately 130 µm on 
the object side. The singlet lens designs were previously described. 74 The 
numerical aperture (NA) was 0.5, which provides sufficient three-
dimensional resolution for functional imaging of neuronal cell bodies and 
processes. The GRIN lens was incorporated into a two-photon fluorescence 
microscope equipped with a 5× air objective of 0.16 NA (Zeiss), which 
generated the initial focus of the excitation light (of 0.2 NA, to match the 0.19 
NA of the GRIN lens on the image side) to be relayed by the GRIN lens to 
the sample side. The two-photon fluorescence signal was collected and 
transported back to the microscope by the GRIN lens and detected with a 
photomultiplier tube (PMT; H7422; Hamamatsu Corporation, NJ, USA). A 
Ti:Sapphire femtosecond oscillator (Mai Tai HP; Spectra-Physics, CA, USA) 
tuned to 940 nm was used as the excitation light source for all experiments. 
Eight weeks after surgery, the mice were habituated to both the head-
restraint and the in vivo imaging setup. Such habituation consisted of 
escalating durations from 540 minutes over a period of 35 days. 
ScanImage 3.8 (Vidrio Technologies LLC, VA, USA) was used to collect in 
vivo imaging recordings at 1.5 Hz for all mice. Laser power was set to 10% 
(i.e. 4548 mW) and it was consistent among all recordings to avoid brain 
tissue damage by heat. The acquisition speed was limited to 1.5 Hz by the 
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scanning stage galvanometer. 
  
Functional imaging analysis. For the analysis of the two photon 
calcium imaging data, the Calcium Imaging Analysis (CaImAn) package75 
and Non- Rigid Motion Correction (NoRMCorre)76 package were used in 
MATLAB R2018A (The MathWorks Inc., MA, USA). First, imaging 
recordings were motion corrected using the NoRMCorre code. Motion 
corrected recordings were then manually screened for frames containing 
aberrations due to motions that could not be corrected, and such frames 
were noted. A custom written MATLAB script aided in this selection of bad 
frames by giving the frame numbers where there was more than a 4 times 
standard deviation difference between frames. However, the script was only 
used as guidance and all the frames were manually checked. Next, using 
the CaImAn package’s pipeline, regions of interest (ROI) are determined in 
the recordings using a constrained nonnegative matrix factorization (CNMF) 
approach finding the best spatial and temporal components explaining the 
observed fluorescence. This algorithm deals with heavily overlapping and 
neuropil contaminated movies, resulting in a fluorescence per ROI with the 
background signal subtracted. After extraction of the fluorescence per ROI, 
recordings over days were manually aligned to be able to track the same 
ROI over days. However, due to fluctuations in virus expression and 
recording in slightly different Z-planes not every ROI could be found in all 
sessions, resulting in the exclusion of this subset of ROIs. Data were 
displayed as heatmaps, single traces and integral of ∆F/F. 
 
Immunohistochemistry for functional imaging animals. After the 
recordings, to confirm the correct positioning of the lenses and virus 
transductions, immunohistochemistry assays were performed on mice 
brains (data not shown). Mice were deeply anesthetized with isoflurane and 
transcardially perfused with 1× PBS followed by 4% PFA in 1× PBS. Head 
bars and GRIN lenses were carefully removed to avoid damaging brain 
tissue. Whole brains were removed and post-fixed in 4% PFA/PBS for 2 h 
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at 4 °C and subsequently transferred to 1× PBS for storage at 4 °C until 
further processing. Coronal brain sections (50 µm thick) containing the 
striatum were collected in 1× PBS using a vibrating tissue slicer (vibratome; 
Leica VT1200), and freely floating slices were immunostained for green 
fluorescent protein (GFP). Sections were incubated with a blocking solution 
of 1× PBS/0.2% Triton X-100 (PBT) plus 5% normal donkey serum (NDS) 
for 1 h. Sections were then incubated with the primary antibodies chicken 
anti-GFP (1:1000 GFP-1020; Aves Labs, OR, USA) in PBT/2% NDS 
overnight at 4 °C. After rinsing 4 × 10 min in 1× PBS, sections were 
incubated for 2 h with secondary antibody donkey anti-chicken-Alexa Fluor 
594 (1:500; Invitrogen) in PBT/2% NDS at room temperature and washed 
with 1× PBS (4 × 10 min). Sections were mounted with DAPI-Fluoromount-
G aqueous mounting medium (Electron Microscopy Sciences) onto 
Superfrost Plus glass slides (VWR International). Images were taken with 
an AxioZoom.V16 fluorescence microscope.  
 
3.2.7 Extracellular recordings of dorsolateral striatal 
neurons 
 
Microelectrode arrays (MEA). Custom-made microelectrode arrays 
(MEA) were obtained from Innovative Neurophysiology (Durham, NC). The 
MEAs had 16 x 35 µm tungsten electrodes. MEA were encased in dental 
cement (Industrial Grade Grip Cement, powder #675571, liquid #675572, 
Dentsply, York, OA).  
Stereotaxic MEA implantation. At 8-12 weeks of age, mice were 
anesthetized with isoflurane via an E-Z Anesthesia brand vaporizer (E-Z 
Anesthesia, Palmer, PA). A craniotomy above the dorsolateral striatum was 
centered at bregma, +0.75 mm; midline, ±1.90 mm and was extended into 
a concentric square (bregma, ±0.3 mm; midline, ±0.3 mm). The MEA was 
slowly lowered -2.70 mm from the dorsal surface (from bregma) into the 
brain and secured to the skull using 2 anchor screws (MF-5182 bone 
screws; Bioanalytical Systems, Inc, West Lafayette, IN), with the ground 
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wire wrapped around one screw and inserted 2 mm into the cerebellum. The 
array was then encased in a dental cement headcap (Industrial Grade Grip 
Cement, powder #675571, liquid #675572, Dentsply, York, OA). 
Following surgery, the mice recovered for two weeks before starting the 
recordings.  
 
 
Recording Hardware. In vivo electrophysiology recordings were 
performed using an Omniplex-DHP system from Plexon, Inc (Dallas, TX), 
with a motorized commutator from NeuroTek (Toronto, Ontario, Canada), 
with the IV fluid port used to feed in the patch cord to the mouse’s head. The 
wideband signal was acquired at 40k Hz, with an analog high-pass filter of 
7.5 Hz, and a 7.5 kHz low pass filter before the signal was digitized at the 
head stage. The continuous spike data was extracted from the wideband 
signal by applying a 4-pole 500 Hz Butterworth high pass filter and a 4-pole 
3000 Hz Butterworth low pass filter. Common median referencing was used 
for all recording sessions. 
 
Data Processing and Analysis. Plexon OfflineSorter 4 was used to 
process and separate identified units from each recording. Units from the 
same electrode were considered to be separate as long as the waveforms 
were significantly separated in 3D principal component space as tested by 
multivariate ANOVA (p<.05), with L-ratios <0.05 for each cluster. 
 
3.2.8 Statistical analysis 
 
Data are reported as mean ± SEM unless otherwise noted. Statistical 
analyses were performed using the Analysis ToolPak 
of Microsoft Excel 2016 (Microsoft Corporation, WA, USA) and GraphPad 
Prism (Prism version 7, GraphPad software, La Jolla, California) or 
OriginPro v9.2 (OriginLab Corporation, MA, USA). Statistical significance (p 
values) for paired comparisons was determined by two-tailed Student’s t 
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test, and p < 0.05 was considered statistically significant. Experimenters 
were blinded during the clinical trial but not for the animal study.  
Relationship between mouse plasma or human blood THC 
concentrations and ammonia concentrations was examined using 
Pearson’s correlation. Behavior data were analyzed with the Analysis 
ToolPak of Microsoft Excel 2016, ANY-maze (Stoelting Co., IL, USA), 
GraphPad Prism, and MATLAB R2017B. Data from calcium imaging and 
electrophysiological recordings were analyzed with MATLAB R2017B (The 
MathWorks Inc., MA, USA) and Prism (Prism version 7, GraphPad software, 
La Jolla, California.  
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4. RESULTS 
 
 4.1 Human Study 
 
  4.1.1 Demographics 
The cohort for this pilot study consisted of 14 cannabis users with a 
mean (±SEM) age of 29.9 (±2.7). The sample had 10 males and 4 females, 
11 African Americans and 4 Caucasians. Seven subjects reported current 
nicotine smoking and 14 were alcohol drinkers but none met alcohol abuse 
or dependence criteria.77 The subjects reported starting cannabis use 
around ages 14.6 (±0.9). The cumulative duration of cannabis use was 9.8 
(±2.1) years; the average number of joints/week was 61.8 (±27.0) while the 
peak number was 86.1 (±29.7) joints/weeks.  
 
4.1.2 Plasma ammonia concentration  
 
Plasma ammonia concentrations increased significantly in subjects 
who received active cannabis compared to placebo (Figure 3.A). The 
baseline showed an important individual variability in ammonia 
concentrations, probably due to the confounding effect of the nicotine 
smoking, since ammonia is a natural component of tobacco leaves 78 and 
also used as an additive to commercial cigarettes.79 Two-way ANOVA with 
time and route effects revealed a significant main effect of time 
[F(8,256)=4.597, p<0.0001], and route [F(3,32)=4.339, p<0.05], but no 
interaction between the two factor [F(24,256)=1.044, p=0.4]. Multiple 
comparisons demonstrated significant differences: placebo vs edible 
marijuana group at 30 min (p<0.05) and 90 min (p<0.05), and at 90 min 
placebo vs vaporized (p<0.05) and smoking routes (p<0.05). The 
concentrations of plasma ammonia positively correlated with the blood THC 
concentration (Figure 3.B, Pearson’s r=0.012, n=297, p<0.05). 
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Figure 3. Cannabis administration increases plasma ammonia concentration. 
A. Plasma ammonia concentration (mean ± SEM) mg/dL in healthy volunteers administered 
with cannabis through different routes of administration versus placebo measured at 
baseline (0), 2, 4, 6, 8, 10, 15, 30, and 90 min post dose. B. Correlation between plasma 
ammonia concentration and blood THC concentrations at all the time points. 
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4.2 Animal Study 
 
 The pattern of delayed increase in plasma ammonia 
concentration observed in the human study could not be explained by 
simple diffusion of inhaled ammonia from the lung to systemic circulation. 
For this reason, we hypothesized that THC itself might be able to increase 
ammonia concentration in the brain, and this ammonia can then diffuse back 
through the blood brain barrier into the blood circulation, leading to the 
observed delayed increase in plasma ammonia concentration at 30 and 90 
min after cannabis administration.  
To test our hypothesis, in the animal study we administered THC 
instead of the cannabis plant which is known to contain ammonia.  
 
4.2.1 Effect of THC on spontaneous locomotor activity  
   
We found a reduction in the locomotor activity after the administration 
of both doses (3 and 10mg/kg) of THC compared to 5 min baseline (Δ 
locomotor activity). Two-way ANOVA with time and THC treatment (0 mg/kg, 
3 mg/kg, and 10mg/kg) revealed a significant effect of time F(34, 
714)=45.34, p<0.0001, treatment F(2,21)=12.48, p<0.0001, and interaction 
between the two factors F(68, 714)=2.754, p<0.0001. Post hoc t-test 
showed significant reduction in locomotor activity compared to 0mg/kg in 
the 3 mg/kg dose at 15, 22–25, 27 and 30 min and in the 10 mg/kg dose at 
2, 5, 6, 9–15, 17–27 and 30 min post injection (Figure 4.A) 
The overall Δ locomotor activity (Figure 4.B) was significantly 
reduced [(F=17.41, p<0.0001) by one-way ANOVA], in both active THC 
dose groups: between 0mg/kg and 3 mg/kg [mean difference and 95% 
CI=58.0, 18.2–97.8, p<0.001] and 0mg/kg and 10mg/kg doses [mean 
difference and 95% CI=90.49, 56.0-125.0, p<0.0001] by Dunnett's multiple 
comparisons test.  
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Figure 4. THC decreases spontaneous locomotor activity in mice. A. 
Locomotor activity (mean ± SEM) measured as distance travelled before and after THC 
injection at the timepoint 0 (n=8 for each group of treatment). B. Overall (at all the time 
points between 0 and 30 min) Δ locomotor activity for the 3 different doses. THC 3 and 10 
mg/kg were compared to 0 mg/kg. 
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4.2.2 Effect of THC on plasma, liver and brain ammonia 
concentration  
 
No significant difference among the first three time points (min 1, 3 
and 5) was found, so data were pooled together. Within this early time 
window THC administration was not associated with changes in plasma 
ammonia concentration (F=0.679, p=0.5, Figure 5.A) and no correlation 
between plasma THC and plasma ammonia concentrations (r=-0.085, 
p=0.3, Figure 5.B) was found. However, comparing plasma ammonia 
concentrations between treatment groups at 30-min post injection showed 
significant difference [F(2,21)=3.682, p =0.042], driven mainly by the 3 
mg/kg THC group [3 mg/kg vs.0 mg/kg: 0.13470.00 vs.0.12270.00, t=2.329, 
df=13, p=0.03, Figure 5.C]. Concentrations of plasma THC were not 
assessed at the latest time point. 
 
 
Figure 5. THC increases plasma ammonia concentration only 30 min post-injection. 
A. Plasma ammonia concentration at min 1, 3 and 5 (n=32). B. Correlation between plasma 
THC and plasma ammonia concentrations at min 1, 3 and 5. C. Plasma ammonia 
concentration at min 30 (n=8).    
 
Liver ammonia concentration was not changed by THC (F=2.308, 
p=0.1, data not shown) at any timepoint.  
 
Furthermore, we found a significant increase in ammonia level in the 
striatum of mice treated with THC (F=4.298, p=0.016, Figure 6.A) and 
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significant positive correlation (r=0.321, p<0.001, Figure 6.B) between 
striatal ammonia and plasma THC concentrations during the first 5 min. At 
the 30-min time point, was observed a 10-fold increase in striatal ammonia 
concentration [F(2,20)=4.043, p=0.033, Figure 6.C] induced by both THC 
doses [3 mg/kg vs. 0mg/kg: 0.24370.02 vs.0.02470.00, t=10.87, df=13, 
p<0.0001 and 10mg vs.0mg/kg: 0.08070.00 vs.0.02470.00, t=5.784, df=14, 
p<0.0001].  
 
 
 
Figure 6. THC increases striatal ammonia concentration 5- and 30-min post-injection. 
A. Ammonia concentration in the striatum at min 1, 3 and 5 (n=32). B. Correlation between 
plasma THC and striatal ammonia concentrations at min 1, 3 and 5. C. Ammonia 
concentration in the striatum at min 30 (n=8).    
 
On the other hand, we measured no changes in ammonia levels in 
PFC (F=1.617, p=0.2) or cerebellum (F=0.076, P=0.9), nor correlation 
between plasma THC and ammonia concentrations in either brain region 
[PFC (r=0.116, p=0.2), and cerebellum (r= -0.058, p=0.5)] during the first 5 
min and at 30-min post injection [PFC [F(2,21)=0.1652, p=0.8], cerebellum 
[F(2,21) =1.068, p=0.3] were found. 
 
 
4.2.3 Effect of THC on glutamine synthetase and glutaminase 
enzyme activity 
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We measured striatal GS and GA activity in three brain regions, such 
as striatum, cerebellum e prefrontal cortex (PFC), within the first 5 minutes 
after THC administration. We found significant reduction of GS activity 
(F=3.243, p<0.05) caused by the 10mg/kg dose (for control vs. THC 10 
mg/kg = 28.1671.5 vs.23.1171.3, p<0.05, Figure 7.A) and negative 
correlation between plasma THC and striatal GS activity (r= -0.284, p<0.05, 
Figure 7B). We did not observe similar THC effect on GS activities in PFC 
(F=0.494, p=0.6) or cerebellum (F=0.929, p=0.4) and there was no 
correlation between plasma THC and GS activities in these brain regions 
(PFC: r=-0.143, p=0.2, Figure 5D, cerebellum: r=-0.199, p =0.13). 
 
 
Figure 7. THC decreases glutamine synthetase (GS) activity in the striatum. A. GS 
activity in the striatum at min 1, 3 and 5 (n=32). B. Correlation between plasma THC and 
striatal ammonia concentrations at min 1, 3 and 5.  
 
GA activity did not show either any significant changes (F=0.146, 
p=0.8), in PFC (F=0.047, p=0.9), and cerebellum (F=1.348, p=0.2) or 
correlation with plasma THC concentration in the striatum (r=0.023, p=0.8), 
PFC (r=0.024, P=0.8), and cerebellum (r=0.259, p=0.063). 
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4.2.4 Effect of CB1R antagonist NESS 0327 in reversing 
the effect of THC on locomotor activity 
 
To better understand the involvement of CB1 receptor in the effect of 
THC on locomotor activity, we pretreated a group of mice (n=15) with the 
potent neutral CB1 receptor antagonist NESS 0327 (i.p., 0.1 mg/kg) 30 min 
before THC injection in order to block the receptor and eliminate the THC 
effect promoted through this type of receptor.  
NESS 0327 successfully reversed the overall locomotor effects of 
THC (THC vs. Control: *p<0.0001, Figure 8. A) at 20 min post THC injection. 
Remarkably, NESS 0327 did not reverse the THC effect within the first 5 
minutes post-injection (THC Vs. NESS: *p<0.0001; THC+NESS vs. Control: 
**p<0.005, Figure 8. B), suggesting that during this early time window 
hypolocomotion could be not entirely mediated by CB1receptors. 
 
Figure 8. CB1 receptor antagonist NESS 0327 neutralize the overall effect of 
THC on locomotion, but not within the first 5 min. A. Overall Δ locomotor activity 
(percentage change from baseline) at 20 minutes. One group of mice was administered 
with THC (10 mg/kg), a second group was pretreated with neutral antagonist of CB1R 
NESS 0327(0.1 mg/kg) 30 min prior injection of THC (10 mg/kg) and the third group was 
injected with vehicle control.  B. Δ locomotor activity for the three different treatments at the 
first 5 min post THC injection compare to vehicle control. 
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4.2.5 Identification of the best dose of ammonium acetate 
to mimic THC effect on locomotor activity   
 
To prove that part of the effect mediated by THC is determined by the 
region-specific increase in ammonia concentration, we first found the most 
appropriate dose of NH4Ac able to produce effects on locomotor activity 
similar to 10 mg/kg of THC. NH4Ac has been used in several studies to 
induce a hyperammonemic state.80, 81 We used four groups of mice (n=7 
each): vehicle control (distilled water), NH4Ac 1 mM/kg, 3 mM/kg or 5 
mM/kg. The distance travelled was recorded for a 5-minute baseline, then 
after the i.p. injections, mice were placed againin the arena and movements 
recorded for 20 minutes.  
Our results showed that NH4Ac was able to reduce the locomotor 
activity in a dose dependent manner. THC and NH4Ac 3 mM/kg caused 
similar significant reduction of locomotor activity compared to the controls 
(One way ANOVA, Tukey’s multiple comparisons: THC vs Controls: 
*p<0.0001; NH4Ac 1 mM/kg vs. Controls: p=0.0001, NH4Ac 3  mM/kg vs. 
Controls: *p<0.0001 NH4Ac 5 mM/kg vs. Controls: p<0.0001, No 
significative difference between the effect of THC and NH4Ac 3 mM/kg: 
p=0.88 n=8/group, Figure 9).  
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Figure 9. Ammonium acetate (NH4Ac) mimics THC effect on locomotion. 
Comparison of the Δ locomotor activity (percentage change from baseline) at 20 minutes 
after administration of THC (10 mg/kg) and 3 doses of NH4Ac (1, 3 and 5 mM/kg) compare 
to vehicle control (n=15/each group). 
 
4.2.6 Functional imaging of neuronal activity of 
dorsolateral striatal neurons 
 
In order to understand the direct effect of THC on the neuronal activity 
in the dorsolateral striatum and whether is comparable to NH4Ac effect, we 
started a pilot study using in vivo endomicroscopy coupled with genetically 
encoded calcium indicators (GCaMP6s). This technique enables the 
analysis of fluctuations in the intensity of calcium-sensitive fluorophores, as 
an indicator of neuronal activity in awake, head fixed mice.74 
We acquired functional images from dorsal striatum GCaMP6s 
neurons for each mouse (8 neurons, n=2 mice; unilateral) in sessions of 5-
minute baseline, 20-minute after vehicle (TWEEN 80® and saline) injection 
followed by 20 min post injection of THC 10 mg/kg or NH4Ac 3 mM/kg 
depending of the session. Mice were head-restrained during the 
experiment. Due to the setup, drugs were administered under the two-
photon microscope in the dark, through i.p. catheter implanted 3-5 days 
before the first day of recording. Each mouse was exposed to THC or NH4Ac 
with a week of time window to avoid potential confounding effects. 
Our preliminary results (Figure 10) showed a decrease in the calcium 
transient over time (reported as the integral of the fluorescence compared 
to baseline, ∆F/F) in the analyzed striatal neurons after i.p. injection of THC 
and NH4Ac (two tailed paired t-test: controls vs. THC *p<0.001, Controls vs. 
NH4Ac: **p<0.05) 
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Figure 10. THC and NH4Ac similarly reduce the neuronal activity in the striatum 
revealed by calcium imaging with 2-photon endomicroscopy in awake, head fixed 
mice. A. Schematic enlarged view of GRIN lens relaying the focus of the objective into a 
focus inside of the dorsolateral striatum. B. Heat maps for each cell (n=8, animals n=2) 
displaying the change in fluorescence (∆F/F) over time after administration of vehicle 
control (C), ammonium acetate (NH4Ac, A) and THC (T). Each row displays the activity of 
one cell, and red color denotes high activity while dark blue denotes low activity. C. ∆F/F 
calcium transient traces of neuron outlined in Figure 10.B for each of the 3 states. D. Box 
whisker plot of the integrals of neuronal activity during the 3 states, showing statistically 
significant reduction in activity after administration of THC (*p<0.001) and NH4Ac 
(**p<0.05).   
 
4.2.7 Extracellular recordings of dorsolateral striatal 
neurons  
 
In order to analyze the direct effect of THC and ammonia on the 
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action potentials and firing rates of the dorsolateral striatal neurons, we 
started a second pilot study using in vivo electrophysiology on freely moving 
mice. All the in vivo extracellular recordings were conducted in collaboration 
with the laboratory of Dr. Dennis Sparta, Anatomy and Physiology 
Department, University of Maryland, Baltimore, MD.  
The experimental design was similar to the one used for the in vivo 
calcium imaging experiment described above. We acquired extracellular 
recordings from dorsal striatum neurons for each mouse (13 neurons, n=2 
mice; unilateral) in sessions of 5-minute baseline, 20-minute after vehicle 
(TWEEN 80® and saline) injection followed by 30 min post injection of THC 
(10 mg/kg) or NH4Ac (3 mM/kg). Each mouse was exposed only once to the 
compounds to avoid potential confounding effects.  
Preliminary results showed that both THC and NH4Ac were able to 
reduce steadily the firing rate compared to vehicle (two-way ANOVA for 
repeated measures and Dunnett’s test: THC, n = 8, F(1,341)= 52.92; 
p<0.01; NH4Ac, n = 5,p<0.001; Figure 11) 
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Figure 11. THC and NH4Ac similarly reduce the neuronal activity in the striatum revealed 
by in vivo electrophysiology recordings in awake, freely moving mice.  A. Schematic 
illustration of the electrode placement in dorsolateral striatum. B. Change over time curves 
displaying the effect of NH4Ac and THC on the firing rate of dorsal striatal neurons (NH4Ac, n=5; 
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THC, n=8). Results are presented as mean ± SEM of firing rate expressed as a percentage of 
baseline levels. Significant data points (p<0.05) were assessed with one-way ANOVA for 
repeated measures vs. baseline and are represented as un-filled circles in the graph. C, E. 
Representative firing rate histogram showing the decrease in discharge rate of an individual 
neuron following i.p. administration of NH4Ac or THC. Arrowheads indicate the time of injection 
and the treatment administered. D, F. Representative traces of a dorsolateral striatal neuron 
before and after NH4Ac or THC administration. 
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5. DISCUSSION 
 
 5.1 Cannabis and ammonia concentrations 
 
We conducted our research with the aim to elucidate how cannabis 
can modify the concentration over time of ammonia after controlled 
administration, both in human cannabis users and mice. For the first time, 
we demonstrated that cannabis administration is able to increase plasma 
ammonia concentrations in cannabis users in a time- and route of 
administration-dependent manner.   
Using a back translational approach, we demonstrated a significant 
effect of acute THC administration on striatal ammonia concentration 
associated with reduction in GS activity in wildtype mice. The choice of 
testing THC in the animal study instead of cannabis plant was made in order 
to avoid potential confounding effects, since THC (C12H30O2) does not 
contain nitrogenous compounds in its chemical structure, while the cannabis 
plant contains and releases ammonia during heating or smoking47, 48 
Interestingly, the clinical study revealed that cannabis administration 
though different routes of administration led to a different timing in ammonia 
detection in plasma: while smoked and vaporized cannabis significantly 
increased ammonia concentrations at 90 min, an increase in ammonia 
following the oral administration was observed at 30 and 90 min. However, 
despite the presence of ammonia in cannabis plant, such a delay from the 
onset of administration in the observed increase in plasma ammonia 
concentration, suggested a potential direct effect of cannabis in ammonia 
dynamics. Furthermore, after oral intake of the plant, the ammonia 
produced, could have caused only an increase in ammonia concentrations 
in the portal circulation and immediately detoxified in the liver by urea cycle, 
without causing an increase in systemic circulation.   
This hypothesis was supported by our animal study results. In 
accordance with previously published data,82 we found that administration 
of THC immediately leads to a temporary reduction in spontaneous 
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locomotor activity in mice. Then, we measured plasma, liver and brain tissue 
ammonia concentrations at three early time points (1, 3, and 5 min) and a 
late time point at 30 min, which correspond with the locomotor behavioral 
effect of THC. Our data showed that a single dose of THC has no effect on 
plasma or liver ammonia concentrations. However, we found a significant 
increase in striatal ammonia within 5 min post THC injection, with no 
significant changes in the other studied brain regions, and at 30 min. 
However, at 30 min, striatal ammonia concentration in each condition (THC 
0, 3 and 10 mg/kg) resulted lower than at 1,3 and 5 min. This slight general 
increase and decrease in ammonia levels, could be explained with the 
stress induced by the injection in all the treated mice.  
Ammonia assays were performed using a traditional colorimetric 
method, according to the manufacturer’s protocol; we also followed strict 
specimen integrity guidelines by maintaining specimens at 4°C, excluding 
any hemolyzed specimens from analysis. Calibrators, blanks, in-house 
quality controls and specimens were analyzed in duplicate. Absorbance of 
assayed substances was averaged. Liver and brain tissues were 
maintained at an appropriate temperature during the collection and storage; 
all tissue samples were run under the same conditions and at the same time 
in order to minimize variability and allow valid comparisons. All these 
precautions allowed to obtain plasma ammonia values consistent with 
previously reported concentrations57, 82 as well as variability in ammonia 
concentration in different brain regions also consistent with what reported in 
literature., 84, 85, 86, 87  
Interestingly, the increase in the striatal ammonia was coupled with a 
significant transient reduction in GS activity at 1 min, suggesting that THC 
suppresses striatal GS activity and increases brain ammonia concentration 
within minutes from acute THC injection, without mediate any change in 
plasma and liver ammonia concentrations. In support of our data on GS 
enzyme activity, a previous report demonstrated that prenatal administration 
of THC was able to reduce the astrocytic GS expression in mice.88 
Interestingly, striatal GS activity measured at 3 and 5 min or GS activity 
42 
 
measured in other brain areas (data not shown) did not show significant 
change, which suggests that the effect of THC on GS activity is transient 
and brain region specific. The underlying mechanism behind GS 
suppression is not clear. Glutamine accumulation was found to reduce GS 
activity.59 Also the reduction in GS activity could stem from a direct effect of 
THC or indirectly through the reduction of ATP synthesis since GS is an 
energy demanding enzyme. Regardless of the mechanism, slight reduction 
in GS activity could have a noticeable effect on brain ammonia 
concentration given that the activity of brain GS is near maximum 
capacity.88, 89 Moreover, suppression of GS activity, theoretically, leads to 
accumulation of glutamate in the astrocytes and reduced capacity of 
astrocytic glutamate transporter that results in increased synaptic glutamate 
concentration, activation of neuronal NMDA receptors and potential 
neurotoxicity.88  
An increase in ammonia concentration is known to induce NMDA 
receptor-mediated toxic effects in most animal species, altering many of 
brain functions. Hyperammonemia determine an upregulation of NMDA 
glutamate receptors with acute increases intracellular free calcium which, 
activates nitric oxide synthase (NOS) after binding to calmodulin, leading to 
an increased production of nitric oxide (NO). NO is able to activate soluble 
guanylate cyclase, resulting in increased formation of cGMP90, whereas 
their downregulation upon prolonged exposure to ammonia leads to 
impairment of cGMP synthesis that is responsible for intellectual and 
memory deficits in chronic hepatic encephalopathy patients54. Ammonia 
impairs the glutamate/NO/cGMP pathway, which includes interference with 
the activation of soluble guanylate cyclase by NO90. Reduction of cGMP 
synthesized in this pathway has been shown to be responsible for cognitive 
deficits in animals with experimentally induced hyperammonemia or hepatic 
encephalopathy91.  
In our study, the activity of GA was not affected by single THC 
administration at any brain region despite the increase in striatal ammonia 
concentration. This finding is consistent with previous reports showing no 
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changes in GA activity after the induction of acute and chronic moderate 
increase in brain ammonia concentrations.92, 93 
 To study the hypothesis that ammonia could originate in the brain 
after THC administration, and also to mimic the timeline of the clinical trial, 
we quantified the plasma, liver and brain ammonia concentration at a later 
time point (30 min). Remarkably, we found a significant increase in striatal 
ammonia associated with a corresponding increase in plasma ammonia, 
that was not present at the earliest time points, while liver, PFC and 
cerebellar ammonia concentrations did not show any significant changes as 
within the first 5 min.  
 
5.2 Cannabis, ammonia and neuronal activity in the dorsolateral 
striatum 
 
The striatum as a critical component of the basal ganglia thalamo-
cortical circuit, is involved in the mediation of voluntary locomotor activity94. 
In particular, the dorsal part of the striatum, being the main input structure 
of the basal ganglia, an ensemble of integrative subcortical nuclei enabling 
the elaboration of complex motor behavior,95 has been widely studied for its 
role in mediating locomotor impairment under effect of THC. A previous 
study, in vivo electrophysiological recordings in rats injected with acute THC, 
showed a significant reduction in neural activity and altered firing patterns 
in the striatum in parallel with the reduction of spontaneous locomotor 
activity and treadmill activity.96 
It is widely accepted that the cannabis-mediated impairment in the 
locomotor activity occurs through presynaptic inhibition of striatal outputs 
mediated by GABAergic CB1R terminals of interneurons or collaterals from 
striatal MSNs.97, 98 However, blocking the effect of CB1Rs with the neutral 
CB1R antagonist NESS 0327 successfully reversed the overall locomotor 
effects of THC, but not THC effect within the first 5 minutes post-injection, 
suggesting that during this early time window hypolocomotion is not 
mediated entirely by CB1R activity. We tested the hypothesis that THC may 
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alter the excitability of striatal neuronal circuits directly through the activation 
of CB1R and indirectly through increasing ammonia concentration 
comparing the effect of THC and NH4Ac on behavior. In line with previous 
studies,99, 100 our results showed lower spontaneous locomotor activity after 
acute administration of NH4Ac, with a pattern similar to the behavioral effect 
THC mediated.100 To correlate the behavioral effect of the two compounds 
to their ability in modulating the dorsal striatal neuronal activity in awake 
mice, we designed two pilot experiments using 2 state-of-the-art techniques 
such as in vivo calcium imaging and in vivo electrophysiology in awake 
mice.  
For the in vivo calcium imaging experiment, we recorded fluctuations 
in striatal intracellular calcium levels as an indicator of neuronal activity, that 
allows to directly visualize the effects of THC and ammonia on striatal 
neurons involved in the decrease in locomotion. Calcium is a universal 
intracellular signal in eukaryotic cells, and the concentration of free calcium 
in cytoplasm is typically four orders of magnitude lower than the extracellular 
concentration and rises substantially after action potential-driven calcium 
entry. As calcium sensor, we used a fluorescent protein derived from green 
fluorescent protein (GFP) fused with calmodulin (GCaMP6s). GCaMP6s 
alters its conformation in response to calcium binding, increasing the 
fluoresce of GFP. The brightness (changes in fluorescence compared the 
basal fluorescence) is used as an indicator of calcium levels. Then we use 
a two-photon microscope to record calcium fluctuations, which are indicative 
of neuronal action potentials. As we previously discovered for the behavioral 
effects, our preliminary imaging data showed for the first time that injections 
of THC 10 mg/kg and NH4Ac 3 mM/kg cause also similar significative 
reduction of neuronal activity in the dorsolateral striatum.  
Imaging data were further supported from other preliminary results, 
obtained with in vivo electrophysiological recording. In this experiment, we 
showed a significant reduction of the firing rates of striatal neurons (NH4Ac: 
n=5; THC: n=8), compared to baseline and vehicle. Only a previous study 
on chronic hyperammonemia coupled the decrease in exploratory activity 
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with a reduced magnitude of electrically-induced long-term potentiation in 
cortico-striatal synaptic transmission.100 
Taken together, these new findings indicate the possibility that THC 
might alter the excitability of striatal neuronal circuits directly through the 
activation of CB1R and indirectly inducing a transient region-specific 
increase in ammonia concentration.  
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6. LIMITATIONS 
 
Our clinical study reports data on a small number of patients, as well 
as other few limitations intrinsically linked to this kind of studies. Cannabis 
use and alcohol intake of participants right before the study session were 
not taken into account and they might have affected the results. Secondly, 
demographic parameters such as age, gender, body mass index, ethnic 
backgrounds as well as inter-individual differences in nicotine and cannabis 
habits that could have affected ammonia concentrations were not 
considered in our evaluation.   
In the animal study, we only quantified plasma, liver and brain 
ammonia during the first 5 min after the acute administration of THC: studies 
with more frequent sampling over a longer duration and after chronic 
administration of THC are warranted to map the details of brain ammonia 
economy under cannabis use. Furthermore, in the last two experiments we 
showed only preliminary data from a limited sample of animals: my future 
work will complete the ongoing experiments to ensure the cohort size 
needed for statistical purposes.    
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7. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Marijuana is the most abused illicit substance and, at the same time, 
the legalization for its medicinal use is increasing worldwide. Therefore, 
scientific studies become imperative to better understand and prevent 
cannabis effects such as alteration of visuospatial abilities and motor 
coordination, that impair motoric and driving performances. 
The results we presented carry remarkable mechanistic and clinical 
significance for cannabis research. For the first time, plasma ammonia 
concentration has been shown to increase after marijuana/THC 
administration in humans and rodents, indicating that ammonia could be 
generated in the CNS and not peripherally as previously described. 
Furthermore, we were able to use state-of-art technique to show real time 
similarities in the effect of ammonia and THC on the striatal neuronal activity, 
area that showed the significant increase in ammonia after a single 
administration of THC. 
In summary, these results are the first to report effects of THC mediated by 
ammonia and indicating ammonia as potential target to treat some 
cannabis-related side effects. 
In future, more accurate techniques could be required to trace the 
ammonia dynamics after controlled cannabis administration. Recent studies 
have shown differences in marijuana effects between male and female and 
between cannabis users at different ages,82,101,102 and further studies are 
needed to explain the role of ammonia dynamics in these differences. In 
addition, to perform a direct exposure of mice to cannabis smoke could 
elucidate the differences between ammonia produced in the brain and the 
amount absorbed by the lungs after the smoke and vapor inhalation. 
Furthermore, a fundamental goal of neuroscience research is to 
understand how dynamics in neuronal circuits control behavioral outputs. 
However, using wildtype mice strongly limited our ability to target specific 
cell subtypes and/or cellular subdomains. Studies on transgenic mice will 
help to elucidate the effects of THC and ammonia on different 
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subpopulations of MSNs and interneurons in this and related brain regions. 
  
49 
 
8. REFERENCES 
 
1. Schultes RE, Klein WM, Plowman T, Lockwood TE. Cannabis: An example of 
taxonomic neglect. Bot Mus Lealf Harv Univ.1974;23:337-367. 
2. Kuddus M, Ginawi IAM, Al-Hazimi A. Cannabis sativa:  An ancient wild edible 
plant of India. Emir J Food Agric. 2013;25:736-745. 
3. Turner CE, ElSohly MA, Boeren EG. J. Nat. Prod 1980;43:169.  
4. Claussen U, Korte F. Justus Liebigs Ann. Chem 1968;713:162.  
5. ElSohly, HN.; Boeren, EG.; Turner, CE.; ElSohly, MA. The Cannabinoids: 
Chemical, Pharmacologic and Therapeutic Aspects. Agurell, S.; Dewey, WL.; 
Willette, RE., editors. Academic Press; Orlando: 1984. p. 89 
6. W. Hall, L. Degenhardt, Adverse health effects of non-medical cannabis use, 
Lancet, 374 (2009), pp. 1383–1391 
7. Mc Guigon M. Cannabinoids. In: Goldfrank LR, Flomenbaum NE, Lewin NA, et 
al., editors. Goldfrank’s Toxicological Emergencies. 8th ed. New York: McGraw-Hill; 
2006.p.1212–1220 2.  
8. Bagshaw SM, Hagan NA. Medical efficacy of cannabinoids and marijuana: a 
comprehensive review of the literature. J  Palliat Care 18:111–122, 2002 3.  
9. Guy GW, Whittle BA, Robson PJ. The Medicinal Uses of Cannabis and 
Cannabinoids. London: Pharmaceutical Press;2004 
10. Mehmedic Z, Chandra S, Slade D, et al. Potency trends of Δ9-THC and other 
cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic 
Sci. 2010;55(5):1209-1217 
11. Clark PA, Capuzzi K, Fick C. Medical marijuana: medical necessity versus 
political agenda. Med Sci Monit (2011) 17(12):RA249–61.doi:10.12659/ 
MSM.882116 
12. Shoyama Y, Tamada T, Kurihara K, Takeuchi A, TauraF, Arai S, et al. Structure 
and function of d1-tetrahydro cannabinolic acid (THCA) synthase, the enzyme 
controlling the psychoactivity of Cannabis sativa. J Mol Biol (2012). 
doi:10.1016/j.jmb.2012.06. 030 
13. Steppan M, Kraus L, Piontek D, Siciliano V. Are cannabis prevalence estimates 
comparable across countries and regions? Across cultural validation using search 
engine query data. Int J Drug Policy (2012).  
14. European Monitoring Centre for Drugs and Drug Addiction (2018), Cannabis 
legislation in Europe: an overview, Publications Office of the European Union, 
Luxembourg_doi: doi:10.2810/566650  
15. Baron, Eric P. "Comprehensive Review of Medicinal Marijuana, Cannabinoids, 
and Therapeutic Implications in Medicine and Headache: What a Long Strange 
Trip It's Been…." Headache: The Journal of Head and Face Pain 55.6 (2015): 885-
916. 
16.  Fernandez-Ruiz J. Cannabinoid drugs for neurological diseases: what is 
behind? Rev Neurol (2012) 54(10):613–28. 
17. Drug.com. Sativex Oromucosal Spray. Available at: 
50 
 
https://www.drugs.com/uk/sativex-oromucosal-spray-spc-10018.html. 
18. Kolliakou A, Fusar-Poli P, Atakan Z. Cannabis abuse and vulnerability to 
psychosis: targeting preventive services. Curr Pharm Des (2012) 18(4):542–9. 
19. Teesson M, Slade T, Swift W, Mills K, Memedovic S, Mewton L, et al. 
Prevalence, correlates and comorbidity of DSM-IV cannabis use and cannabis use 
disorders in Australia. Aust N Z J Psychiatry (2012). 
20. Olson, Kent R. Poisoning & Drug Overdose. New York: Lange Medical 
Books/McGraw-Hill, 2004. 
21. Tashkin DP. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest 
Dis (2005) 63(2):93–100. 
22. Ivanov I, Pearson A, Kaplan K, Newcorn J. Attention deficit hyperactivity 
disorder and comorbid substance abuse. In: Greydanus DE, Calles JL Jr, Patel DR, 
Nazeer A, Merrick J editors. Clinical Aspects of Psychopharmacology in Childhood 
and Adolescence. New York: Nova Science(2011).p.33–49. 
23. Schizophrenia Commission. The Abandoned Illness: A Report by the 
Schizophrenia Commission. London, England: Rethink Mental Illness; November 
2012. 
24.  Crane NA, Schuster RM, Fusar-Poli P, Gonzalez R. Effects of cannabis on 
neurocognitive functioning: recent advances, neurodevelopmental influences, and 
sex differences. Neuropsychol Rev. 2013;23(2): 117-137. 
25. Ranganathan M, D’Souza DC. The acute effects of cannabinoids on memory 
in humans: a review. Psychopharmacology (Berl). 2006;188(4):425-444. 
26. Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Non-acute (residual) 
neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol 
Soc. 2003;9(5):679-689. 
27. Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive 
performance after prolonged abstinence: a meta-analysis. Exp Clin 
Psychopharmacol. 2012;20(5):420-429. 
28. Paule MG, Allen RR, Bailey JR, et al. Chronic marijuana smoke exposure in 
the rhesus monkey, II: effects on progressive ratio and conditioned position 
responding. J Pharmacol Exp Ther. 1992; 260(1):210-222. 
29. Lane SD, Cherek DR, Pietras CJ, Steinberg JL. Performance of heavy 
marijuana-smoking adolescents on a laboratory measure of motivation. Addict 
Behav. 2005;30 (4):815-828.  
30. Lane SD, Cherek DR. Marijuana effects on sensitivity to reinforcement in 
humans. Neuropsychopharmacology. 2002;26(4):520-529. 
31. Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD. 
Dopaminergic function in cannabis users and its relationship to cannabis-induced 
psychotic symptoms. Biol Psychiatry. 2014;75(6):470-478. 
32. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic 
impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 
1998;28(3):309-369. 
33. Caballero A, Tseng KY. Association of cannabis use during adolescence, 
prefrontal CB1receptor signaling and schizophrenia. Front Pharmacol (2012) 
3:101. 
51 
 
34. Marriott KS, Huffman JW. Recent advances in the development of selective 
ligands for the cannabinoid CB (2) receptor. Curr Top Med Chem (2008) 8(3):187–
204. doi:10.2174/156802608783498014 47.  
35. Guindon J, Hohmann AG. The endocannabinoid system and cancer: 
therapeutic implication. Br J Pharmacol (2011) 163(7):1447–63.  
36. Hibell B, Guttormsson U, Ahlström S, Balakireva O, Bjarnason T, Kokkevi A, et 
al. ESPAD (The European School Survey Project on Alcohol and Other Drugs) 
report2007. Substance Use Among Students in 35 European Countries. 
Stockholm: Swedish Council Information Alcohol Other Drugs (2009).  
37. Eaton DK, Kann L, Kinchen S, Shanklin S, Flint KH, Hawkins J, et al. Youth 
Risk Behavior Surveillance (YRBS)US2009. MMWR Surveill Summ (2010) 59(SS-
5):1–142. 
38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental 
Disorders, DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Association 
(2000). 
39. Iversen L. Cannabis and the brain. Brain (2003) 26(Pt6):1252–70.  
40. Chan GC, Hinds TR, Impey S, Storm DR. Hippocampal neurotoxicity of Delta9-
tetrahydrocannabinol. The Journal of neuroscience: the official journal of the 
Society for Neuroscience 1998; 18(14): 5322-5332. 
41. Campbell VA. Tetrahydrocannabinol-induced apoptosis of cultured cortical 
neurones is associated with cytochrome c release and caspase-3 activation. 
Neuropharmacology 2001; 40(5): 702-709. 
42. Scallet AC, Uemura E, Andrews A, Ali SF, McMillan DE, Paule MG, et al. 
Morphometric studies of the rat hippocampus following chronic delta-9-
tetrahydrocannabinol (THC). Brain research 1987; 436(1): 193-198. 
43. Landfield PW, Cadwallader LB, Vinsant S. Quantitative changes in 
hippocampal structure following long-term exposure to delta 9-
tetrahydrocannabinol: possible mediation by glucocorticoid systems. Brain 
research 1988; 443(1-2): 47-62. 
44. Harper JW, Heath RG, Myers WA. Effects of Cannabis sativa on ultrastructure 
of the synapse in monkey brain. Journal of neuroscience research 1977; 3(2): 87-
93. 
45. Heath RG, Fitzjarrell AT, Fontana CJ, Garey RE. Cannabis sativa: effects on 
brain function and ultrastructure in rhesus monkeys. Biological psychiatry 1980; 
15(5): 657-690. 
46. Rocchetti M, Crescini A, Borgwardt S, Caverzasi E, Politi P, Atakan Z, et al. Is 
cannabis neurotoxic for the healthy brain? A meta-analytical review of structural 
brain alterations in non-psychotic users. Psychiatry Clin Neurosci 2013; 67(7): 483-
492. 
47. Bloor RN, Wang TS, Spanel P, Smith D. Ammonia release from heated 'street' 
cannabis leaf and its potential toxic effects on cannabis users. Addiction 2008; 
103(10): 1671-1677. 
48. Moir D, Rickert WS, Levasseur G, Larose Y, Maertens R, White P, et al. A 
comparison of mainstream and sidestream marijuana and tobacco cigarette smoke 
produced under two machine smoking conditions. Chemical research in toxicology 
2008; 21(2): 494-502. 
52 
 
49. De Pasquale A, Costa G, Trovato A. The influence of cannabis on 
glucoregulation. Bulletin on narcotics 1978; 30(3): 33-41. 
50. Ghoneim MT, Mikhail MM, Mahfouz M, Makar AB. Effect of hashish smoke on 
some blood and serum parameters in rabbits. Die Pharmazie 1980; 35(4): 226-
228. 
51. Keiding S, Sorensen M, Bender D, Munk OL, Ott P, Vilstrup H. Brain 
metabolism of 13N-ammonia during acute hepatic encephalopathy in cirrhosis 
measured by positron emission tomography. Hepatology 2006; 43(1): 42-50. 
52. Ratner S, Morell H, Carvalho E. Enzymes of arginine metabolism in brain. 
Archives of biochemistry and biophysics 1960; 91: 280-289. 
53. Cooper AJ, Jeitner TM. Central Role of Glutamate Metabolism in the 
Maintenance of Nitrogen Homeostasis in Normal and Hyperammonemic Brain. 
Biomolecules 2016; 6(2). 
54. Albrecht J, Sonnewald U, Waagepetersen HS, Schousboe A. Glutamine in the 
central nervous system: function and dysfunction. Frontiers in bioscience: a journal 
and virtual library 2007; 12: 332-343. 
55. Norenberg MD (1977) A light and electron microscopic study of experimental   
portal-systemic  (ammonia)  encephalopathy.  Progression and reversal of the 
disorder. Lab Invest 36:618–627. 
56. Hertz L, Song D, Peng L, Chen Y. Multifactorial Effects on Different Types of 
Brain Cells Contribute to Ammonia Toxicity. Neurochem Res. 2016 Jun 10. [Epub 
ahead of print] PubMed PMID: 27286679 
57. James JH, Escourrou J, Fischer JE. Blood-brain neutral amino acid transport 
activity is increased after portacaval anastomosis. Science 1978; 200(4348): 1395-
1397. 
58. Mans AM, Biebuyck JF, Shelly K, Hawkins RA. Regional blood-brain barrier 
permeability to amino acids after portacaval anastomosis. Journal of 
neurochemistry 1982; 38(3): 705-717. 
59. Jessy J, Mans AM, DeJoseph MR, Hawkins RA. Hyperammonaemia causes 
many of the changes found after portacaval shunting. The Biochemical journal 
1990; 272(2): 311-317. 
60. Cooper AJ, Plum F. Biochemistry and physiology of brain ammonia. Physiol 
Rev 1987; 67(2): 440-519. 
61. Butterworth RF, Girard G, Giguere JF. Regional differences in the capacity for 
ammonia removal by brain following portocaval anastomosis. Journal of 
neurochemistry 1988; 51(2): 486-490. 
62. Wurtman RJ, Fernstrom JD. Control of brain monoamine synthesis by diet and 
plasma amino acids. The American journal of clinical nutrition 1975; 28(6): 638-
647. 
63. Lai JC, Cooper AJ. Neurotoxicity of ammonia and fatty acids: differential 
inhibition of mitochondrial dehydrogenases by ammonia and fatty acyl coenzyme 
A derivatives. Neurochemical research 1991; 16(7): 795-803. 
64. Dynnik VV, Kononov AV, Sergeev AI, Teplov IY, Tankanag AV, Zinchenko VP. 
To Break or to Brake Neuronal Network Accelerated by Ammonium Ions? PloS one 
2015; 10(7): e0134145. 
53 
 
65. Hermenegildo C, Montoliu C, Llansola M, Munoz MD, Gaztelu JM, Minana MD, 
et al. Chronic hyperammonemia impairs the glutamate-nitric oxide-cyclic GMP 
pathway in cerebellar neurons in culture and in the rat in vivo. The European journal 
of neuroscience 1998; 10(10): 3201-3209. 
66. Gorg B, Schliess F, Haussinger D. Osmotic and oxidative/nitrosative stress in 
ammonia toxicity and hepatic encephalopathy. Archives of biochemistry and 
biophysics 2013; 536(2): 158-163. 
67. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R (June 2006). 
"Evaluation of a vaporizing device (Volcano) for the pulmonary administration of 
tetrahydrocannabinol". Journal of Pharmaceutical Sciences. 95 (6): 1308–17. 
doi:10.1002/jps.20574. PMID 16637053.   
68. Scheidweiler KB, Newmeyer MN, Barnes AJ, Huestis MA. Quantification of 
cannabinoids and their free and glucuronide metabolites in whole blood by 
disposable pipette extraction and liquid chromatography-tandem mass 
spectrometry. J Chromatogr A. 2016 Jul 1;1453:34-42. 
doi:10.1016/j.chroma.2016.05.024. 
69. Meye FJ, Trezza V, Vanderschuren LJ, Ramakers GM, Adan RA. Neutral 
antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol 
Psychiatry. 2013 Dec;18(12):1294-301. doi: 10.1038/mp.2012.145. 
70. Jeyaraj D, Scheer FA, Ripperger JA, Haldar SM, Lu Y, Prosdocimo DA, Eapen 
SJ, Eapen BL, Cui Y, Mahabeleshwar GH, Lee HG, Smith MA, Casadesus G, Mintz 
EM, Sun H, Wang Y, Ramsey KM, Bass J, Shea SA, Albrecht U, Jain MK. Klf15 
orchestrates circadian nitrogen homeostasis. Cell Metab. 2012 Mar 7;15(3):311-
23. doi: 10.1016/j.cmet.2012.01.020. 
71. Momosaki S, Ito M, Tonomura M, Abe K. Assessment of glutamine synthetase 
activity by [13N] ammonia uptake in living rat brain. Synapse 2015; 69(1): 26-32. 
72. Blanco E, Pavon FJ, Palomino A, Luque-Rojas MJ, Serrano A, Rivera P, et al. 
Cocaine-induced behavioral sensitization is associated with changes in the 
expression of endocannabinoid and glutamatergic signaling systems in the mouse 
prefrontal cortex. The international journal of neuropsychopharmacology 2015; 
18(1). 
73. Chen TW, Wardill TJ, Sun Y, Pulver SR, Renninger SL, Baohan A, Schreiter 
ER, Kerr RA, Orger MB, Jayaraman V, Looger LL, Svoboda K, Kim DS. 
Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature. 2013 
Jul18;499(7458):295-300. 
74. Bocarsly ME, Jiang WC, Wang C, Dudman JT, Ji N, Aponte Y. Minimally 
invasive microendoscopy system for in vivo functional imaging of deep nuclei in 
the mouse brain. Biomed Opt Express. 2015 Oct 23;6(11):4546-56.  
75. Pnevmatikakis EA, Soudry D, Gao Y, Machado TA, Merel J, Pfau D, Reardon 
T, Mu Y, Lacefield C, Yang W, Ahrens M, Bruno R, Jessell TM, Peterka DS, Yuste 
R, Paninski L. Simultaneous Denoising, Deconvolution, and Demixing of Calcium 
Imaging Data. Neuron. 2016 Jan 20;89(2):285-99. 
76. Pnevmatikakis, E.A. and A. Giovannucci, NoRMCorre: An online algorithm for 
piecewise rigid motion correction of calcium imaging data. Journal of neuroscience 
methods, 2017. 291: p. 83-94. 
77. American Psychiatric Association. (2013). Diagnostic and statistical manual of 
mental disorders (5th ed.). Washington, DC: Author. 
54 
 
78. Heini HG, Gebhardt R, Brecht A, Mecke D. Purification and characterization of 
rat liver glutaminase. Eur J Biochem 1987; 162(3): 541-546. 
79. Whitlatch A, Schick S. Thirdhand Smoke at Philip Morris. Nicotine Tob 
Res.2018 Jul 20. doi:10.1093/ntr/nty153. [Epub ahead of print] PubMed PMID: 
30053240. 
80. Witt AM, Larsen FS, Bjerring PN. Accumulation of lactate in the rat brain during 
hyperammonaemia is not associated with impaired mitochondrial respiratory 
capacity. Metab Brain Dis. 2017 Apr;32(2):461-470. doi:10.1007/s11011-016-9934-
7. Epub 2016 Dec 7. PubMed PMID: 27928693. 
81. Cittolin-Santos GF, de Assis AM, Guazzelli PA, Paniz LG, da Silva JS, 
Calcagnotto ME, Hansel G, Zenki KC, Kalinine E, Duarte MM, Souza DO. 
Guanosine Exerts Neuroprotective Effect in an Experimental Model of Acute 
Ammonia Intoxication. Mol Neurobiol. 2017 Jul;54(5):3137-3148. 
doi:10.1007/s12035-016-9892-4. Epub 2016 Apr 6. PubMed PMID: 27052954. 
82. Javadi-Paydar M, Nguyen JD, Kerr TM, Grant Y, Vandewater SA, Cole M, Taffe 
MA. Effects of Δ9-THC and cannabidiol vapor inhalation in male and female rats. 
Psychopharmacology (Berl). 2018 Sep;235(9):2541-2557. doi:10.1007/s00213-
018-4946-0. Epub 2018 Jun 16. PubMed PMID: 29907926. 
83. Grzeda E, Wisniewska RJ. Effect of the class I metabotropic glutamate receptor 
antagonist AIDA on certain behaviours in rats with experimental chronic 
hyperammonemia. Adv Med Sci 2009; 54(2): 269-276. 
84. Willems EW, Rambali B, Vleeming W, Opperhuizen A, van Amsterdam JG. 
Significance of ammonium compounds on nicotine exposure to cigarette smokers. 
Food Chem Toxicol 2006; 44(5): 678-688. 
85. Lee A, Lingwood BE, Bjorkman ST, Miller SM, Poronnik P, Barnett NL, et al. 
Rapid loss of glutamine synthetase from astrocytes in response to hypoxia: 
implications for excitotoxicity. J Chem Neuroanat 2010; 39(3): 211-220. 
86. Sarna GS, Bradbury MW, Cremer JE, Lai JC, Teal HM. Brain metabolism and 
specific transport at the blood-brain barrier after portocaval anastomosis in the rat. 
Brain research 1979; 160(1): 69-83. 
87. Swamy M, Zakaria AZ, Govindasamy C, Sirajudeen KN, Nadiger HA. Effects 
of acute ammonia toxicity on nitric oxide (NO), citrulline-NO cycle enzymes, 
arginase and related metabolites in different regions of rat brain. Neurosci Res 
2005; 53(2): 116-122. 
88. Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR, et 
al. Cannabinoid structure-activity relationships: correlation of receptor binding and 
in vivo activities. The Journal of pharmacology and experimental therapeutics 
1993; 265(1): 218-226. 
89. Krajnc D, Neff NH, Hadjiconstantinou M. Glutamate, glutamine and glutamine 
synthetase in the neonatal rat brain following hypoxia. Brain research 1996; 707(1): 
134-137. 
90. Rodrigo R, Monfort P, Cauli O, Erceg S, Felipo V. Pharmacological 
manipulation of cyclic GMP levels in brain restores learning ability in animal models 
of hepatic encephalopathy: therapeutic implications. Neuropsychiatr Dis Treat. 
2006 Mar;2(1):53-63. 
91. Erceg S, Monfort P, Hernandez-Viadel M, Llansola M, Montoliu C, Felipo V. 
55 
 
Restoration of learning ability in hyperammonemic rats by increasing extracellular 
cGMP in brain. Brain Res. 2005 Mar 2;1036(1-2):115-21. 
92.Suarez I, Bodega G, Fernandez-Ruiz JJ, Ramos JA, Rubio M, Fernandez B. 
Reduced glial fibrillary acidic protein and glutamine synthetase expression in 
astrocytes and Bergmann glial cells in the rat cerebellum caused by delta(9)-
tetrahydrocannabinol administration during development. Dev Neurosci 2002; 
24(4): 300-312. 
93. Cooper AJ, Mora SN, Cruz NF, Gelbard AS. Cerebral ammonia metabolism in 
hyperammonemic rats. Journal of neurochemistry 1985; 44(6): 1716-1723. 
94. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999; 58(4): 
315-348. 
95. Gerfen CR, Surmeier DJ. Modulation of striatal projection systems by 
dopamine. Annu Rev Neurosci. 2011;34:441-66. doi: 10.1146/annurev-neuro-
061010-113641. Review. PubMed PMID: 21469956; PubMed Central PMCID: 
PMC3487690. 
96. Shi, L.H., et al., Dose and behavioral context dependent inhibition of movement 
and basal ganglia neural activity by Delta-9-tetrahydrocannabinol during 
spontaneous and treadmill locomotion tasks in rats. Synapse, 2005. 55(1): p. 1-16. 
97. Pickel, V.M., et al., Compartment-specific localization of cannabinoid 1 (CB1) 
and mu-opioid receptors in rat nucleus accumbens. Neuroscience, 2004. 127(1): 
p. 101-12. 
98. Kofalvi, A., et al., Involvement of cannabinoid receptors in the regulation of 
neurotransmitter release in the rodent striatum: a combined immunochemical and 
pharmacological analysis. J Neurosci, 2005. 25(11): p. 2874-84. 
99. Rangroo Thrane, V., et al., Ammonia triggers neuronal disinhibition and 
seizures by impairing astrocyte potassium buffering. Nat Med, 2013. 19(12): p. 
1643-8. 
100. Chepkova, A.N., et al., Impaired novelty acquisition and synaptic plasticity in 
congenital hyperammonemia caused by hepatic glutamine synthetase deficiency. 
Sci Rep, 2017. 7: p. 40190. 
101. Albertella L, Le Pelley ME, Copeland J. Frequent Cannabis Use Is Associated 
With Reduced Negative Priming Among Females. Exp Clin Psychopharmacol. 
2016 Jun 23. [Epub ahead of print] PubMed PMID: 27337025. 
102. Richter L, Pugh BS, Ball SA. Assessing the risk of marijuana use disorder 
among adolescents and adults who use marijuana. Am J Drug Alcohol Abuse. 2016 
Jun13:1-14. 
 
